Ranbaxy taps U.S. exec as regulatory watchdog

Last week, Ranbaxy Laboratories surprised many pharma-watchers with an 11th-hour approval for its copycat version of the Pfizer ($PFE) blockbuster Lipitor. The company had been promising it would launch its atorvastatin generic on time, true. But Ranbaxy also faced continuing problems with the FDA--problems it had been trying to resolve for years.

Now, the company may be one step closer to a final settlement with the agency, The Economic Times reports. The Indian paper says Ranbaxy has appointed a senior executive in the U.S. specially tasked with keeping the company out of regulatory hot water. Putting Manjeet Bindra, Ranbaxy USA's VP of quality, in charge of "data reliability" and compliance answers the FDA's demands for a permanent regulatory point person, the paper says.

The Economic Times' sources say Bindra's appointment is one of several steps Ranbaxy has agreed to as part of a consent decree with the agency that is expected to be signed soon. The agreement will also include a penalty of $350 million to $400 million, the Times reports. And it would allow the company to resume selling some 30 products made in India that have been under an import alert since December 2008. Ranbaxy wouldn't comment about Bindra's appointment or on the possibility of a consent decree.

- read the Times story

Suggested Articles

Having only just completed an expansion in Illinois, PCI Pharma Services will now expand its solid dose facility in Wales in the U.K.

The FDA has come down on a small U.S. drugmaker for taking a skin medication to market even though there were out-of-spec test results at release.

Merck & Co. set out to answer the question of whether lung cancer patients with KRAS mutations respond as well to Keytruda as others do.